Charles River Laboratories (CRL) Tops Q3 EPS by 12c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $3.09, $0.12 better than the analyst estimate of $2.97. Revenue for the quarter came in at $982.7 million versus the consensus estimate of $960.16 million.
GUIDANCE:
Charles River Laboratories sees FY2026 EPS of $11.35-$11.55, versus the consensus of $11.38.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
- Amcor plc (AMCR) Misses Q1 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
